Physician profile
Frank Grady
NPI 1003819517
$799.60
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $783 · 2022: $17.00.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $548.82 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $115.94 | 2019 | |
| Sun Pharmaceutical Industries INC. | $47.30 | 2019 | |
| Novartis Pharmaceuticals Corporation | $29.05 | 2019 | |
| Shire North American Group INC | $24.84 | 2019 | |
| Ocular Therapeutix, INC. | $17.00 | 2022 | |
| Akorn, INC. | $16.65 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Grady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.